Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03
Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
KMD | Ann: KMD Brands Group CEO Succession | 02/10/24 | 0 | 60 | |||
|
|||||||
KMD | Ann: FY24 Annual Results Announcement | 25/09/24 | 0 | 84 | |||
|
|||||||
KMD | Ann: Amended SPH Notice - FirstCape Group Limited | 17/09/24 | 0 | 68 | |||
|
|||||||
KMD | Ann: SPH Notice - FirstCape Group Limited | 16/09/24 | 0 | 73 | |||
|
|||||||
KMD | Ann: Closing Date for Director Nominations | 05/09/24 | 0 | 61 | |||
|
|||||||
KMD | Ann: KMD Brands Constitution | 05/09/24 | 0 | 62 | |||
|
|||||||
KMD | Ann: FY24 Release Date | 28/08/24 | 0 | 54 | |||
|
|||||||
KMD | Ann: FY24 Results Release Date | 28/08/24 | 0 | 57 | |||
|
See All Discussions